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Abstract 
Background: HIV-1 integration is prone to a high rate of failure, resulting in the accumulation of unintegrated viral 
genomes (uDNA) in vivo and in vitro. uDNA can be transcriptionally active, and circularized uDNA genomes are bio-
chemically stable in non-proliferating cells. Resting, non-proliferating CD4 T cells are prime targets of HIV-1 infection 
and latently infected resting CD4 T cells are the major barrier to HIV cure. Our prior studies demonstrated that uDNA 
generates infectious virions when T cell activation follows rather than precedes infection.
Results: Here, we characterize in primary resting CD4 T cells the dynamics of integrated and unintegrated virus 
expression, genome persistence and sensitivity to latency reversing agents. Unintegrated HIV-1 was abundant in 
directly infected resting CD4 T cells. Maximal gene expression from uDNA was delayed compared with integrated 
HIV-1 and was less toxic, resulting in uDNA enrichment over time relative to integrated proviruses. Inhibiting integra-
tion with raltegravir shunted the generation of durable latency from integrated to unintegrated genomes. Latent 
uDNA was activated to de novo virus production by latency reversing agents that also activated latent integrated 
proviruses, including PKC activators, histone deacetylase inhibitors and P-TEFb agonists. However, uDNA responses 
displayed a wider dynamic range, indicating differential regulation of expression relative to integrated proviruses. 
Similar to what has recently been demonstrated for latent integrated proviruses, one or two applications of latency 
reversing agents failed to activate all latent unintegrated genomes. Unlike integrated proviruses, uDNA gene expres-
sion did not down modulate expression of HLA Class I on resting CD4 T cells. uDNA did, however, efficiently prime 
infected cells for killing by HIV-1-specific cytotoxic T cells.
Conclusions: These studies demonstrate that contributions by unintegrated genomes to HIV-1 gene expression, 
virus production, latency and immune responses are inherent properties of the direct infection of resting CD4 T cells. 
Experimental models of HIV-1 latency employing directly infected resting CD4 T cells should calibrate the contribu-
tion of unintegrated HIV-1.
Keywords: HIV-1, Latency, Unintegrated DNA, Raltegravir, Integration, Cytotoxic T cells
© 2016 Chan et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The failure of the majority of HIV-1 reverse transcripts 
to integrate into cellular chromosomal DNA has been 
apparent since the initial molecular descriptions of 
infection in  vivo and in  vitro [1, 2] (reviewed in [3, 4]). 
Unintegrated HIV-1 DNA (uDNA) can be transcrip-
tionally active, and production of early viral RNA and 
proteins has been observed in several cell types includ-
ing resting CD4 T cells [5, 6]. The number of transcrip-
tionally active uDNA genomes can rival the number of 
active integrated proviruses [7]. Integration-defective 
lentiviral vector systems exploit this transcriptional activ-
ity, as well as biochemical stability of circularized extra-
chromosomal genomes in non-replicating cells [8–11] to 
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achieve sustained ectopic gene expression in multiple lin-
eages in vitro and in vivo (reviewed in [12]). uDNA gene 
expression is higher in non-proliferating cells compared 
with proliferating cells such as transformed cell lines and 
activated CD4 T cells, perhaps owing to a lack of dilution 
of uDNA templates and their RNA and protein products 
[4, 13].
We have previously reported that when cellular coin-
fection places an integrated provirus (iDNA) in a cell 
together with an unintegrated genome, viral comple-
mentation allows completion of the unintegrated virus’ 
replication cycle without integration [14]. Recently, we 
reported that when HIV-1 infects resting T cells several 
days prior to T cell activation, uDNA alone generates 
infectious virions [6]. This stands in contrast to infec-
tion of activated T cells or cell lines, which support only 
transient and reduced levels of gene expression from 
uDNA without de novo virus production. Also in con-
trast to activated T cells and cell lines, gene expression 
from uDNA in resting T cells required delivery of virion-
associated Vpr, evidence of the uniqueness of uDNA 
gene regulation. The sequence of events which we found 
to induce production of infectious virions from uDNA 
mimics an in  vivo situation where an infected resting 
CD4 T cell is activated following migration to lymphoid 
tissues, which has been proposed as a mechanism facili-
tating the establishment of HIV-1 infection [15–17].
The predominant model for establishment of HIV-1 
latency entails the infection of an activate CD4 T cell 
that returns to a resting state, thus removing support for 
viral transcription [18]. On the other hand, during acute 
and early infection, resting CD4 T cells are frequent tar-
gets of infection, constituting up to 90 % of viral RNA+ 
cells in both HIV-1 infected humans and SIV infected 
macaques [19, 20]. The latent reservoir is also rapidly 
established during acute infection [21–23], supporting 
the notion that direct infection of resting CD4 T cells 
may also contribute to the latent reservoir [19, 24, 25]. 
The majority of infected cells during untreated chronic 
infection also contain only unintegrated HIV–1 DNA 
[26]. Although unstimulated peripheral blood T cells are 
resistant to infection in  vitro [27], in  vivo, HIV-1 repli-
cates in lymphoid (LT) and mucosal tissues that provide 
microenvironmental factors (cytokines, chemokines, 
DC and stromal cells) that support HIV-1 replication 
and maintain cell viability [28, 29]. Several important 
in vitro models of HIV-1 latency utilize these factors to 
promote survival of resting CD4 T cells in  vitro and to 
increase their permissiveness to infection by HIV-1 [30]. 
These systems are extensively utilized to test the response 
of latent HIV-1 to various compounds under scrutiny as 
latency reversing agents for curative therapies.
To this end, we recently described a convenient and 
relevant model system [6] in which resting peripheral 
blood CD4 T cells are treated with common gamma 
chain cytokines such as IL-4 that render them permis-
sive to infection without inducing cell activation, though 
it is known that common gamma chain cytokines induce 
signaling pathways such as stat5 or stat6 and increase the 
expression of the survival protein Bcl-2 [31, 32]. IL-4, 
which we employ here, has been implicated in facilitating 
HIV-1 replication in lymphoid tissues [33] and, as a prod-
uct of various immune cells including T cells [34], assists 
HIV transcription [35]. Recently we have shown that the 
primary function of primary gamma chain cytokines in 
assisting infection of resting CD4 T cells in vitro is to pre-
vent HIV-1-induced cell death early after infection that is 
triggered by reverse transcription and virion Vpr, rather 
than to enhance specific replicative processes [36]. With 
this system, we observed that latency persisted in rest-
ing CD4 T cells for several weeks, after which de novo 
virus production could be elicited by T cell activation. 
Importantly, using either the integrase inhibitor raltegra-
vir or class I integrase mutants, we observed that durable, 
reversible latency was efficiently established by uninte-
grated HIV-1. Neither stimulation of cell activation nor 
virus expression induced proviral integration in this sys-
tem. Virus production from uDNA was about one order 
of magnitude lower than from integrated proviruses but 
per-virion, was equally infectious [6].
In the present study we investigated the properties of 
uDNA and integrated proviruses (iDNA) in resting CD4 
T cells, finding substantial and unexpected differences 
in the kinetics of their gene expression, persistence and 
virus production. We compared the responsiveness of 
latent unintegrated and latent integrated HIV-1 to a 
series latency reversing agents. Finally, we investigated 
the capacity of uDNA to down modulate Class I HLA 
expression and to prime infected cells for CTL killing. We 
conclude that unintegrated HIV-1 should be accounted 
for in models employing direct infection of non-prolif-
erating cells such as resting CD4 T cells. Should these 
mechanisms pertain in vivo, the persistence of non-pro-
liferating cells expressing HIV-1 proteins from uDNA 
may be threatened more by anti-HIV immunity than by 
biochemical degradation or viral cytopathic effects.
Results
Kinetics of gene expression by integrating 
and non‑integrating HIV‑1 in resting CD4 T cells
This study utilizes envelope-defective single round GFP 
reporter viruses expressing GFP in place of Nef, with Nef 
expressed at wild type levels downstream of an IRES ele-
ment [37]. GFP fluorescence is generated during both 
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the early and late gene expression phases, providing a 
sensitive measurement of overall HIV-1 gene expression 
that is highly correlated with virus production [6, 38]. To 
examine the properties of unintegrated genomes, inte-
gration was inhibited either with raltegravir (RAL) or by 
mutation of HIV-1 integrase at the catalytic domain [39], 
which we have previously demonstrated are functionally 
equivalent [6, 14], inhibiting integration by at least 2–3 
orders of magnitude.
Given the long life span of resting CD4 T cells and 
the stability of circularized HIV-1 uDNA in them, we 
investigated the kinetics of gene expression from uDNA 
vs. iDNA in these cells after a single round of infection 
(Fig.  1). In the absence of further stimulation, integra-
tion-competent HIV-1 (No RAL) attained peak num-
bers of productively infected (GFP+) cells 7–9 days post 
infection (p.i.), consistent with studies demonstrating 
slowed kinetics of infection processes in resting vs. acti-
vated T cells [27, 40]. Unintegrated HIV-1 (+RAL) dis-
played even slower expression kinetics, with expression 
remaining very low during the first 7–9 days, consistent 
with prior studies examining short term infections [41]. 
uDNA expression peaked around 2 weeks after infection, 
and parallel results were obtained using a class I integrase 
mutant (Additional file 1: Fig. S1A). At peak expression, 
nearly as many GFP+ cells were generated from unin-
tegrated as from integration-competent HIV-1 (Fig. 1c), 
though uDNA GFP MFI was four fold lower (Additional 
file 1: Fig. S2A) and HIV-1 RNA levels were 6.3 fold lower 
(Additional file 1: Fig. S2B). No increase in the numbers 
of cells expressing GFP was observed after day 14–16, 
suggesting that by this time the majority of both inte-
grated and unintegrated genomes which were destined 
to be spontaneously active had done so; therefore, this 
interval could be useful to study durable latency in the 
GFP-negative cells. In order to be particularly cautious 
regarding raltegravir efficacy [42], we added this inte-
grase inhibitor 3 times over the course of the experiment, 
achieving a reduction from 0.48 integrated genomes 
per GFP +cell to less than or equal to 0.002 iDNA cop-
ies per GFP+ cell, i.e. less than one in 500 GFP+ cells 
contained an integrated provirus. (Additional file 1: Fig. 
S2C). In addition, the conformity of the raltegravir and 
integrase mutant results confirms that reversal of ralte-
gravir activity is not playing a role. To test the effect of 
virus inoculum size on expression from uDNA, we 
reduced the virus inoculum eightfold, yielding a peak of 
2  % GFP+ cells with the integration competent virus, 
or increased it twofold, observing little or no alteration 
in the kinetics of virus expression or the relative expres-
sion from the No RAL vs. +RAL infections (Additional 
file 1: Fig. S3A). Important for subsequent latency stud-
ies in GFP-negative cells, little HIV-1 RNA was expressed 
(Additional file  1: Fig. S2B). As mentioned above, we 
recently reported that common gamma chain cytokines 
enhance in vitro infection of peripheral blood resting T 
cell primarily by allowing them to survive early reverse 
transcription- and Vpr-induced apoptosis rather than 
through enhancement of virus replication per se [36]. 
Here and in prior work [6] we found that GFP+ cells 
were almost exclusively found among the cells which did 
not proliferate. GFP+ cells showed identical cell cycle 
status as demonstrated by staining for pyronin Y/7AAD 
(not shown and [36]). CD69 is increased in GFP+ No 
RAL cells as we previously demonstrated, secondary to 
HIV-induced suppression of Foxo1 activity [43].
Next, we stimulated the entire cell population consist-
ing of both GFP+ cells that are productively infected as 
well as the GFP-negative cells that comprise both unin-
fected and non-productively infected cells (Fig.  1a–c). 
αCD3/CD28 beads induce T cell activation, while the 
combination of a PKC activator prostratin (Pro) and a 
histone deacetylase inhibitor trichostatin A (TSA) more 
directly activates virus transcription. Integration-com-
petent HIV-1 (Int-WT, No RAL) responded strongly to 
each stimulus beginning 1 day after infection (assayed on 
day 3). However, induction of maximal uDNA expression 
was only achieved with stimulation from day 7 (assayed 
on day 9) onward, demonstrating the uDNA requires 
more time than iDNA to establish responsiveness to 
these virus stimuli. There was a stimulation-induced 
increase in the GFP fluorescence of pre-existing GFP+ 
cells for both No RAL and +RAL cultures. However, 
stimulation increased the number of GFP+ cells only in 
the +RAL cultures, while the No RAL cultures remained 
at similar percentages of GFP+ cells. As we will describe 
in Fig.  5, there is rapid death of GFP+ cells only in No 
RAL cultures and this is accelerated by further stimula-
tion. As a result, stimulation-induced cell loss masks 
latency reversal in No RAL cultures here, necessitating 
removal of pre-existing GFP+ cells to specifically exam-
ine latency reversal, which is specifically explored in the 
following figures. Equivalent results were obtained using 
the Int-D116 N mutant (Additional file 1: Fig. S1A). Thus, 
not only does uDNA display slower expression kinetics, 
its availability for transactivation is delayed compared 
with integrating HIV-1 and indicates qualitative differ-
ences in gene regulation between iDNA and uDNA.
Importantly, two distinct peaks of GFP expression 
appeared in the No RAL cultures treated with Pro/
TSA days 5–7 (assay days 7–9, arrows in Fig.  1b). PCR 
analysis in our previous study indicated that the dim-
mer peak corresponds primarily to expression from 
unintegrated genomes, while cells in the brighter peak 
contain at least one integrated provirus [6]. Consistent 
with this, the bright population was lost upon raltegravir 
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Fig. 1 Kinetics of responsiveness to activating agents following initial infection of resting CD4 T cells. a Experimental design. After infection, 
samples of the IL-4-treated resting CD4 T cells were maintained in culture with or without raltegravir (RAL) for the indicated time period and were 
then stimulated by αCD3/CD28 activation beads or prostratin plus trichostatin (Pro/TSA) for 2 days before analysis by flow cytometry. IL-4 was 
replenished every 7 days. Raltegravir was added on the day of infection and on days 3, 7, 14 and 21. b Emergence of GFP+ productively infected 
cells. Pro/TSA or αCD3/CD28 beads were added 2 days prior to analysis. Only the GFP+ cells are displayed, and the areas under the curves represent 
the number of GFP+ cells present in each sample. Red arrows indicate subpopulations which we have previously shown to contain predominantly 
unintegrated HIV-1 (uDNA) or to contain at least one copy of integrated HIV-1 DNA (iDNA) [6]. One representative of 5 experiments is shown. Addi-
tional file 1: Fig. S1A in presents a similar experiment performed using an Int-D116N integrase active site mutant. c Percentage of cells that were 
GFP+. Experiment was performed in triplicate. To account for proliferation of GFP-negative cells, %GFP+ was calculated as the number of GFP+ 
cells divided by the number of total live cells, which was adjusted for proliferation using the Expansion Index in the Proliferation Platform of FlowJo 
9. Cell divisions were measured by eFluor670 dilution. Typically ≤16 % of cells underwent division through day 14, with essentially all of them GFP-
negative (Additional file 1: Fig. S4A). d Cell populations predominantly expressing HIV-1 from unintegrated (GFPlow) or integrated HIV-1 (GFPhi) 
can be parsed in αCD3/CD28 activated T cells by accounting for cellular heterogeneity (side scatter [SSC] profile). Equivalent results were obtained 
utilizing the Int-D116N active site mutant (Additional file 1: Fig S1B)
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treatment (Fig.  1d) or Int-D116N mutation (Additional 
file  1: Fig S1B). Pro/TSA increased HIV-1 expression 
with little change in cell phenotype, including size and 
scatter profile (Fig. 1d). As a result, these cells remained 
largely homogeneous, and variations in GFP expression 
were easily discerned. By contrast, αCD3/CD28 beads 
generated a high degree of cell heterogeneity, which we 
hypothesized to have masked these subpopulations in the 
histograms of Fig. 1b. In fact, these two subpopulations 
were revealed in the activated T cells when the side scat-
ter (which reports cell heterogeneity) and GFP expression 
were plotted together (Fig. 1d, Additional file 1: Fig S1B). 
Therefore, separate and distinct populations expressing 
HIV-1 from both integrated and unintegrated templates 
is a common phenomenon when resting CD4 T cells are 
stimulated several days after infection.
Response of latent unintegrated vs. integrated 
HIV‑1 to a series of latency reversing agents
We next examined latent uDNA responses to several 
latency reversing agents (LRA) being considered as com-
ponents of curative therapies. To this end, we established 
14-day infections with the single round GFP reporter 
virus in the presence or absence of maximally effective 
raltegravir (Fig.  2a) and sorted eFluor670hiGFP-nega-
tive cells. Maintenance of the resting CD4 T state after 
sorting was evidenced by lack of expression of activa-
tion markers and G0-G1a cell cycle status in >99.3 % of 
eFluor670hiGFP-negative cells (Additional file  1: Figure 
S4). We then applied a panel of LRA or combinations of 
LRA, including PKC activators, HDAC inhibitors and 
P-TEFb agonists. We measured GFP fluorescence and 
virus release 24  h after stimulation (Fig.  2b). All LRA 
which were effective on integration-competent HIV-1 
were also effective in reversing latency from uDNA. 
Prior studies, including our own, have found that unin-
tegrated retroviral genomes are responsive to histone 
deacetylase inhibitors [6, 44–46], which we confirm. 
Similar results were obtained in multiple experiments 
with either raltegravir (Additional file 1: Fig. S5) or with 
the Int-D116N virus (not shown). Infection without spi-
noculation resulted in a reduced infection frequency 
but the responses of latently infected cells to LRA were 
similar to spinoculated cells (not shown). Sorted eFluor-
670lowGFP-negative cells, the proliferated population, did 
not generate GFP+ cells either spontaneously or follow-
ing addition of latency reversing agents (not shown). This 
is interesting because homeostatic proliferation does not 
substantially alter the latent reservoir in vitro [47], thus 
neither productive infection nor latency in our system 
were efficiently established in cells which subsequently 
proliferated.
Strikingly, but also consistent with Fig.  1, at least as 
many and usually more GFP+ cells were generated from 
the +RAL infections for each LRA than from the No 
RAL infections (Fig. 2b, c). This held true for infections at 
lower and higher MOI (Additional file 1: Fig. S3B) and for 
Int-D116  N viruses (not shown). An expanded panel of 
LRA produced similar results (Additional file 1: Fig. S5, 
and Expt. 2 in Fig. 3c, d, g, f ). Fewer virions were gener-
ated from the +RAL cells in each culture (Fig.  2d), and 
fewer virions were released per GFP+ cell (Fig. 2h) that 
was consistent with the lower transcription from uninte-
grated genomes. Virus production was highly correlated 
with GFP fluorescence intensity similarly for the No RAL 
and +RAL infections (Fig.  2f ). However, the dynamic 
range of the induction of both GFP+ cells and the GFP 
fluorescence intensities were greater for the +RAL infec-
tions (bracketing lines in Fig. 2e, f ). This translated into 
the finding of Fig. 2g, where, as the strength of the acti-
vators increased (more virions were released), the +RAL 
virus production approached closer to the No RAL virus 
production (Fig. 2g). This increase in the relative output 
from the +RAL infections was the result of both more 
GFP+ cells being generated as well as an increase in 
the output per cell relative to the No RAL cells (Fig. 2h), 
(See figure on next page.) 
Fig. 2 Activation of latent integration-competent HIV-1 and unintegrated HIV-1 with a panel of latency reversing agents (LRA). a Experimental 
design. Raltegravir was added on days 0, 3 and 7 and not removed until sorting. b The responses of latently infected cells to various LRAs under No 
RAL and +RAL conditions, expressed as the percentage of GFP+ cells 1 day after stimulation. Data from one experiment representative of >3 inde-
pendent experiments with cells from different donors is shown. Each condition was tested in triplicate. Additional file 1: Figure S5 shows an inde-
pendent experiment (Experiment 2 in Fig. 3c, d, g, h) employing an expanded panel of LRA. Similar results were obtained with the Integrase D116N 
mutant (not shown). c The percentage of GFP+ cells generated in the No RAL vs. the +RAL cultures for each LRA in two independent experiments 
from b (Expt. 1) and in Additional file 1: Fig. S5 (Expt. 2). Each symbol represents one LRA from Fig. 2b (Experiment 1) and S5 (Experiment 2). d Virus 
production from No RAL vs. +RAL cultures for both experiments. e The percentage of GFP+ cells generated by various LRAs vs. virus release into 
the culture medium to compare virus production per GFP+ cell. The dynamic range is shown for the number of GFP+ cells and for virus production 
as fold induction of the maximum over the minimum value. Data are from Expt. 1 and is representative of 3 additional independent experiments. f 
GFP Mean fluorescence intensity (MFI) of the GFP+ cells vs. virus production for No RAL and +RAL cells in Expt. 1. Similar results were obtained from 
Expt. 2 (not shown). The dynamic ranges are shown as in e. g Relationship between the strength of the LRA in inducing virus production (X axis) and 
the +RAL output expressed as a percent of the No RAL output. +RAL output reached 66 % of No RAL output for Bryostatin+ SAHA. h Relationship 
between the strength of the LRA in inducing virus production (X axis) and the +RAL output per GFP+ cell expressed as a percent of the No RAL 
output per GFP+ cell. c–h All p ≤ 0.001
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consistent with the greater dynamic range seen in the 
GFP fluorescence (Fig. 2f ). These results further indicate 
that uDNA latency and transactivation are regulated dif-
ferently from integrated proviruses.
With regard to individual LRA and classes of LRA, the 
PKC agonists (prostratin, bryostatin) were overall the 
most effective, activating viruses within the most cells 
and inducing the most virus production from both inte-
grating and unintegrated HIV-1 (Fig. 2b, Additional file 1: 
Fig S5). Histone deacetylase inhibitors [TSA, SAHA 
(vorinostat), Scriptaid] and the P-TEFb agonists JQ1 and 
HMBA only weakly activated latent integrated or unin-
tegrated viruses on their own, but they enhanced virus 
activation in combination with PKC activators, consist-
ent with the possible enhancement of stochastic fluctua-
tions in transcription [48]. Disulfiram was ineffective in 
our system on either integrating or unintegrated HIV-1, 
consistent with other recent reports [49, 50]. Interest-
ingly, synergy between agents was obtained only with 
PKC activators plus HDACi or JQ1 and only in the ralte-
gravir cultures (Table 1). This provides further evidence 
that uDNA and iDNA are differentially regulated at the 
transcriptional level.
A recent study indicated that HIV-1 constructs ren-
dered incapable of replicating by mutations or deletions 
of the env gene can revert to wild type through recombi-
nation with envelope expression plasmids following co-
transfection of producer cells [51]. To test if replication 
competent viruses might be contributing to our results, 
we treated infected resting CD4 T cells with the protease 
inhibitor indinavir on the day of infection and on day 5 
post infection with the non-nucleoside reverse tran-
scriptase inhibitor efavirenz in order to block the spread 
of any reverted viruses. There was no effect on the gen-
eration of latently infected cells, indicating that reversion 
was not contributing to results (not shown).
Kinetics of latency reversal
Twenty-four hours after stimulation of latently infected 
cells is a convenient and frequently utilized time at 
which to analyze latency reversal [30]. However, our data 
indicating differential regulation of uDNA and iDNA 
prompted us to test if uDNA also presents differential 
kinetics of latency reversal. To this end, we performed 
a latency experiment with cells from 3 donors, sorting 
eFluorhiGFP- cells 14 days after infection then stimulat-
ing them with Pro/TSA. We analyzed the emergence of 
GFP expression and virus production over the follow-
ing 3  days (Fig.  3). During the initial 14  h the No RAL 
cells generated from 3.7 to 7.9 fold more virus than the 
+RAL cells (Fig.  3b, c). However, after this initial burst 
of production, the relative differences in virus output 
decreased (Fig.  3c). With Donor 3 cells, which had the 
highest initial infection frequency, the +RAL virus pro-
duction even exceeded the No RAL production by 2 days 
after stimulation. We then calculated virus output per 
GFP+ cell, accounting for the differences in the number 
of GFP+ cells and changes in their numbers over time 
(Fig. 3d). On a per-cell basis the rate of virus production 
from the No RAL cells decreased relative to the +RAL 
cells. For Donor 3 cells, the output per GFP+ cell equaled 
the No RAL cells after 2 days. Thus, uDNA latency rever-
sal initially displayed slower kinetics compared with inte-
grated proviruses, but the differences in virus production 
between the No RAL and +RAL declined over time, indi-
cating a more sustainable virus release from uDNA.
Distribution of integrated and unintegrated 
genomes in productive infection and latency
We next analyzed the content of cells for integrated and 
unintegrated HIV-1 before and after latency reversal. 
Fourteen days after direct infection of resting CD4 T 
cells, we sorted cells into 4 groups based on GFP fluo-
rescence intensity (Fig. 4a). Using qPCR we then directly 
measured total HIV-1 genomes, integrated proviruses 
and 2-LTR circles (Fig. 4b). The primers to measure total 
DNA amplify all integrated and unintegrated species of 
HIV-1 DNA. 2-LTR circles have been observed to be 
formed as a minor fraction of the unintegrated species, 
forming about 1/30th of the total uDNA, with 1-LTR cir-
cles and linear uDNA constituting the remainder [52, 53]. 
The overall amount of uDNA is calculated as total DNA 
minus integrated DNA.
The most obvious result, consistent with prior studies 
[54, 55], was that uDNA was formed in excess of inte-
grated proviruses. In this infection of resting T cells, 
uDNA was present on day 14 p.i. at nearly tenfold excess 
over iDNA (Additional file 1: Table S1) amongst all cells 
(GFP+ and GFP-neg.). Cells with the highest GFP fluo-
rescence (+++ cells corresponding to the prominent 
peak in Fig.  1b) contain at least one integrated genome 
consistent with prior results [6, 14]. By contrast, single + 
and double ++ cells contained less than one iDNA per 
cell (0.2 and 0.3 in the + and ++ cells, respectively), thus 
between 67 and 80  % of these dimmer cells expressed 
GFP from uDNA only. In 5 similar experiments utiliz-
ing 5 different cell donors, a substantial fraction of GFP+ 
cells (9–62  %) contained only uDNA (Additional file  1: 
Table S2).
To examine the contribution of unintegrated DNA to 
latency we treated sorted GFP-negative cells with Pro/
TSA (Fig. 4c), then performed a second sort and analyzed 
the DNA content of GFP-neg. and GFP+ cells (Fig. 4d). 
Similar to the initial infection, uDNA predominated in 
the GFP dim cells while there was at least one integrated 
provirus in the GFP bright cells. Interestingly, uDNA was 
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Fig. 3 Kinetics of latency reversal and virus production from sorted GFP-negative cells following in vitro infection of resting CD4 T cells from 3 
donors. The 14-day latency protocol from Fig. 2a was followed using cells from 3 HIV-negative donors following infection with equal amounts of 
HIV-1 in order to investigate kinetics of latent virus activation and donor variability. For added precaution against de novo infection, Indinavir was 
added at day 0 and 7 p.i., while efavirenz was added at day 5 p.i. for donors 2 and 3. a Percent GFP+ cells after Pro/TSA or DMSO carrier control 
treatment of sorted GFP-negative cells. Percent GFP+ cells prior to sort (No RAL, +RAL): Donor 1: 4.9 %, 3.3 %, Donor 2: 16.9 %, 22.4 %, Donor 3: 
21.4 %, 17.3 %. b Virions released into culture medium measured by RT-qPCR for genomic viral RNA. Lower limit of quantitation was 1 virion/µl. c 
The difference in virus output from the No RAL and +RAL cultures decreases over time following latency reversal. Graphs present the ratio of No 
RAL virus output vs. +RAL virus output over the indicated interval. Output over each interval for No RAL and +RAL cells was calculated by subtract-
ing the virions/µL at the earlier indicated time from the later time, then the ratio of No RAL/+RAL was graphed. For example, for Donor 1 during the 
first 14 h (“0–14”) the No RAL cells released 7.3 times as many virions as the +RAL cultures but over the 41–65 h interval, the No RAL cells release 2.2 
times as many virions as the +RAL cells. Red line indicates equal output from the No RAL and +RAL cells. d The difference in virus output per GFP+ 
cell from the No RAL and +RAL cultures decreases over time following latency reversal. The ratio of No RAL virus output per GFP+ cell vs. +RAL 
virus output per GFP+ cell over the indicated interval. Output during each interval, calculated as in 3C was then divided by the percent GFP+ cells 
at the end of each interval. For example, for Donor 1 during the first 14 h (0–14) each GFP cell in the No RAL infections released 9.5 times as many 
virions as the +RAL GFP+ cells but during 41–65 h interval, the No RAL cells released 2.9 times as many virions per GFP+ cell. Red line indicates 
equal output from the No RAL and +RAL cells
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still the majority population in the bright cells. A prior 
study in proliferating cells has shown that unintegrated 
genomes can constitute a similar proportion of tran-
scriptionally active genomes as integrated proviruses 
[7], however ours is the first study conducted in resting 
CD4 T cells and to directly parse cell subpopulations and 
analyze DNA content. There were 20 times more uDNA 
than iDNA genomes in the GFP-negative cells from the 
first sort, but only 5.5 times as many in the newly acti-
vated GFP+ cells from the second sort (Additional file 1: 
Table S1) indicating that silent iDNA genomes were more 
likely to be activated by the Pro/TSA treatment than were 
silent uDNA genomes, a result consistent with the dif-
ferential latency regulation. There could also be a higher 
proportion of defective or otherwise unresponsive uDNA 
than iDNA genomes. Importantly, no increase in integra-
tion resulted from this stimulation 15 days after infection 
(Fig. 4b vs. d, Additional file 1: Table S1), consistent with 
the short (1  day) half-life of pre-integration complexes 
[56].
Consistent with Fig. 1, raltegravir increased the gener-
ation of GFP+ cells from the latent pool (3.2 vs. 1.88 %) 
while inhibiting integration by ≥280 fold (Fig.  4e–h). 
Raltegravir also increased the appearance of 2-LTR 
circles by several fold (Fig. 4f ), as expected [6, 57, 58]. 
As in the No RAL cultures, no increase in integration 
resulted from this stimulation 14  days after infection, 
in agreement with our prior study utilizing both ralte-
gravir and integrase active site mutants [6], but in con-
trast to a recent study in which removal of raltegravir 
2–3 days after infection allowed integration to proceed 
[42]. The difference in results from that study to ours is 
likely to be the considerable differences in the timing 
between infection and the removal of raltegravir. In the 
current study we left raltegravir in the culture for the 
duration of the 14 days prior to sorting and added it 2 
additional times on days 3 and 7. The measured quan-
tity of residual integration events in Fig. 4f and h, likely 
caused by an integrase-independent mechanism, cannot 
account for the expression of HIV-1 in the raltegravir-
treated cultures.
Persistence of cells expressing HIV‑1 
from unintegrated genomes
The lower but more sustained gene expression and de 
novo virus production from uDNA vs. iDNA suggested 
the possibility that these are less cytopathic to cells 
when uDNA is the template. Lower cytopathicity could 
enhance uDNA persistence and allow more prolonged 
virus release from the uDNA template. To test this, at day 
7 post infection we sorted GFP+ cells infected with an 
integrase WT HIV-1 or an Integrase active site mutant 
(Integrase D116N), then analyzed cell survival of the 
sorted GFP+ cells and virus production from them in the 
absence of further stimulation (Fig. 5a). As we predicted, 
the GFP+ cells productively infected with the integrase 
mutant died at a considerably lower rate than cells pro-
ductively infected with the integrase WT virus, and they 
generated 27 % of the total de novo virus output from the 
Integrase WT virus over this time. After about 12 days in 
these cells the death curve of the Int-WT virus inflected 
to be approximately parallel with the Int-D116N virus, 
suggesting that cells expressing GFP from integrated 
viruses may have become depleted from the Int-WT 
infected cells, with relative enrichment of cells expressing 
GFP from uDNA (shown to arise in Fig. 4) in this non-
replicating cell population.
To test this hypothesis, we sampled productively 
infected cells at 3 intervals after infection and analyzed 
their DNA content (Fig.  5b–d). Here we employed a 
reporter virus expressing the cell surface molecule 
Table 1 Synergy indices for  combinations of  latency 
reversing agents
Synergy indices were calculated from 3 independent experiments with different 
cell donors, based on the number of GFP+ cells. Synergy was calculated 
according to [95] and synergy indices significantly >1 are indicated in italicized 
text. Additional file 1: Figure S5 contributes data for one of the 3 experiments
No RAL +RAL
Bryostatin
 +TSA 1.06 ± 0.13 1.49 ± 0.28
 +SAHA 0.94 ± 0.07 1.09 ± 0.05
 +Scriptaid 0.95 ± 0.05 1.19 ± 0.09
 +JQ1 0.85 ± 0.06 1.14 ± 0.10
 +HMBA 0.92 ± 0.13 1.12 ± 0.16
 +Disulfiram 0.83 ± 0.06 0.79 ± 0.03
Prostratin
 +TSA 1.02 ± 0.04 1.44 ± 0.14
 +SAHA 0.96 ± 0.08 1.30 ± 0.19
 +Scriptaid 0.97 ± 0.05 1.42 ± 0.18
 +JQ1 0.87 ± 0.07 1.19 ± 0.16
 +HMBA 0.63 ± 0.10 0.77 ± 0.29
 +Disulfiram 0.55 ± 0.14 0.68 ± 0.14
JQ1
 +TSA 0.72 ± 0.08 0.88 ± 0.22
 +SAHA 0.87 ± 0.11 0.90 ± 0.11
 +Scriptaid 0.84 ± 0.15 0.90 ± 0.10
HMBA
 +TSA 0.63 ± 0.17 0.78 ± 0.03
 +SAHA 0.62 ± 0.21 0.81 ± 0.11
 +Scriptaid 0.69 ± 0.14 0.91 ± 0.14
Disulfiram
 +TSA 0.68 ± 0.11 0.72 ± 0.13
 +SAHA 0.63 ± 0.06 0.69 ± 0.06
 +Scriptaid 0.85 ± 0.17 0.98 ± 0.19
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Heat Stable Antigen (HSA, a.k.a. murine CD24) in 
place of GFP [43] which allows purification of produc-
tively infected (HSA+) cells with anti-HSA magnetic 
beads. Between days 5 and day 7 there was no loss of 
either integrated or unintegrated HIV-1 DNA in these 
cells infected without raltegravir added (Fig.  5c, d). 
However, between days 7 and 14 there was a nine-
fold reduction in the integrated proviruses among 
the HSA+ cells but only a 2.6 fold reduction in total 
DNA at day 7 p.i., consistent with our hypothesis that 
the cells expressing virus solely from the uDNA tem-
plate have a survival advantage over cells expressing 
virus from an integrated template. Confirming our 
model, HSA+ cells collected on day 7 from the No 
RAL condition died at a greater rate than either the 
HSA− cells or HSA+ cells from raltegravir treated 
culture (Fig.  5e). Cells expressing HIV-1 from uDNA 
(+RAL, HSA+ cells) died at a similar rate to the HSA-
negative cells, confirming that uDNA gene expres-
sion is not particularly toxic. All of the cells from day 
14 died at an equal rate, which is consistent with the 
observed depletion of cells expressing HIV from iDNA 
by this point. In separate experiments, αCD3/CD28 
beads accelerated death of purified No RAL HSA+ 
(or GFP+) cells but not +RAL HSA+ (or GFP+) cells 
(Additional file 1: Fig. S6). Thus, owing to its reduced 
toxicity, genetically active uDNA can have a persis-
tence advantage in resting, non-proliferating T cells 
compared with active integrated proviruses.
One or two rounds of stimulation do not activate 
all unintegrated latent genomes
The efficacy of any shock and kill regimen will require 
that essentially all replication competent HIV–1 
genomes be activated. Prior studies, however, have 
demonstrated failure of single or repeated strong stim-
uli to accomplish this in ex  vivo and in  vitro systems 
[59, 60]. Here, we investigated whether a single round 
of strong stimulation can activate all unintegrated latent 
genomes (Fig.  6). Fourteen days after infection, we 
treated sorted eFluorhiGFP-neg. Cells with Pro/TSA, 
or activated them with αCD3/CD28 beads plus IL-2, or 
left them untreated (First Stimulation) (Fig. 6b, c). The 
αCD3/CD28 beads induced cell enlargement and prolif-
eration in ≥99 % of the cells, indicating essentially com-
plete activation. Pro/TSA, which does not induce T cell 
activation, resulted in no cell enlargement or prolifera-
tion but similar HIV-1 induction. We counted the total 
number of GFP+ cells generated from the GFP-nega-
tive sorted cells, and calculated the percent GFP+ cells 
based on the number of cells placed in each well before 
the first stimulation (Fig. 6c). Three days later we sorted 
GFP-neg. cells a second time from each culture and (re)
stimulated them with one of the agents or with nothing 
(Second Stimulation). This yielded 9 combinations of 
first and second stimuli (Fig. 6d). We calculated the per-
cent GFP+ cells based on the number of cells placed in 
each well before the second stimulation (Fig. 6e). Stimu-
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Fig. 4 Distribution of integrated and unintegrated HIV-1 DNA after infection resting CD4 T cells and following latency reversal. Data are representa-
tive of 5 experiments (see Additional file 1: Table S1 for all experiments). Mean of triplicate PCR and SD are shown. ND none detected. a At Day 14 
p.i., eFluorhi cells from No RAL cultures were sorted based on 4 levels of GFP fluorescence (blue boxes indicate sorting gates). b Sorted cells were 
analyzed by qPCR for total HIV-1 DNA, 2-LTR circles and integrated proviruses. c GFP-negative cells were sorted, then stimulated with Pro/TSA for 
1 day, and then sorted a second time based on GFP expression. d Sorted cells were analyzed for viral DNA as in b. e–h The procedures of a–e were 
performed on raltegravir treated cells
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Fig. 5 Preferential loss of resting CD4 T cells infected with integrated proviruses. a Productively infected GFP+ cells containing Int-WT or Int-D116N 
HIV-1 were sorted by FACS 7 days after infection and placed back into culture. Survival of the GFP+ cells was assessed by flow cytometry on the 
indicated days, and virus production from the FACS purified GFP+ cells was measured by RT-qPCR for viral RNA present in the culture medium as 
described [6]. In this experiment an Envelope+ virus was employed. b Experimental design for c–e. Resting CD4 T cells infected with HSA-reporter 
viruses were maintained in IL-4 ± RAL for 14 days. At the indicated time points HSA+ cells in each sample were isolated using anti-HSA antibody 
coupled to magnetic beads. Efavirenz was added to all cells on day 8. HSA Positive and negative cells were separated using the MACS system. Cell 
survival was measured by forward and side scatter analysis. Data present one of two independent experiments. c Productively infected HSA+ cells 
purified from No RAL cultures at day 5, 7 and 14 p.i. were analyzed for viral DNA. d The ratios of 2-LTR/total HIV-1 DNA in comparison with the ratio 
of integrated/total HIV-1 DNA for No RAL purified HSA+ productively infected cells. e HSA+ and HSA-neg. cells were purified at day 7 and 14 p.i. and 
placed into fresh medium. Cell viability of these individual populations was monitored by flow cytometry over 48 h
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cells generated in the second round. However, a second 
stimulation nevertheless generated measurable num-
bers of GFP+ cells. These finding held true in both the 
raltegravir treated and untreated cultures. In fact, more 
GFP+ cells were generated in the raltegravir cultures in 
the first and second round stimulations, with the excep-
tion of cells that were activated by αCD3/CD28 beads in 
the first round. We previously demonstrated [6] that cell 
proliferation antagonizes uDNA gene expression, so it 
seems likely that that this effect plus the partitioning of 
uDNA genomes as the cells divided reduced the num-
ber of uDNA genomes that could be activated in αCD3/
CD28 activated cells.
In a variant of this experiment, we stimulated cells 
infected with the single round virus twice (day 8 and 
day 11 post infection) prior to sorting for GFP-nega-
tive cells. Similar to Fig.  6, we observed latent viruses 
emerge 2  days later with or without further stimula-
tion, further confirming a strong stochastic component 
to latency reversal (Additional file  1: Fig. S7). Overall, 
these results indicate that both uDNA latency and inte-
grated proviral latency can resist a single or even dou-
ble exposure to stimuli intended to reverse the latent 
state.
Failure to down modulate HLA Class I expression 
and CTL responses to HIV‑1 epitopes expressed 
from integration competent and defective HIV‑1
Observations of gene expression from uDNA prompted 
the notion that this could expand the antigenic rep-
ertoire of HIV-1 and the number of cells vulnerable 
to CTL recognition [61]. We first measured the abil-
ity of uDNA to down modulate receptors required for 
immune recognition. In our system, integration-com-
petent HIV-1 efficiently down modulated CD4 (Fig. 7a) 
and HLA Class I (Fig. 7b) in the majority of either rest-
ing CD4 T cells or cells subsequently activated accord-
ing to the post-infection activation (Post-activation) 
procedures utilized in this work and in our prior study 
[6] which demonstrated that high level uDNA expres-
sion is only achieved by this sequence of events and not 
by infection of pre-activated T cells. Post-activation 
of the cells resulted in the death of more GFP+ cells 
than GFP-neg. cells, resulting in a decrease in the per-
cent GFP+. HLA Class I down modulation by the inte-
grating virus was biphasic and observed only in cells 
with GFP expression higher than achieved by uDNA. 
HIV-1 Nef-dependent HLA Class I down modulation 
(reviewed in [62]) has been shown to inhibit CTL rec-
ognition [63]. Similar to previous reports [64] uDNA 
was able to down modulate CD4, though not as effi-
ciently as integrating virus. On the other hand, HLA 
Class I was barely affected by uDNA gene expression, 
suggesting continued high vulnerability to CTL recog-
nition might result.
Next, we examined the ability of HIV-1-specific CTL to 
recognize and eliminate cells expressing HIV-1 proteins 
from unintegrated templates (Fig.  7c). CD8 cytotoxic T 
cell lines specific for HIV-1 Nef and Gag were developed 
from HIV-1 infected individuals as previously described 
[65, 66]. These CTL lines were co-cultured with HIV-
1-infected HLA Class I-matched target cells at vary-
ing CTL to target cell ratios. Negative controls included 
HLA Class I mismatched infected target cells. Killing 
of HIV-1 expressing cells was measured as a reduction 
in the percentage of GFP+ cells by flow cytometry, and 
non-specific killing of the HLA Class I mismatched cells 
was subtracted from these data. Both Gag-specific and 
Nef-specific CTL recognized and eliminated GFP+ cells 
expressing HIV-1 proteins from HIV-1 with wild-type 
integrase or from uDNA (Int-D116N) with the efficiency 
of killing titrating according to the CTL:target ratio. Per-
haps not-surprisingly, given the weaker expression of Gag 
vs. Nef from uDNA [6], CTL against Gag more efficiently 
killed Int-WT infected cells than Int-D116N infected 
cells. This would be consistent with a recent study indi-
cating that 2-LTR uDNA is cleared less efficiently by 
CTL than integrated proviruses [67]. On the other hand, 
Nef CTL more efficiently killed cells infected with the 
integrase deficient virus, so uDNA clearance could be 
epitope-specific. It is tempting to speculate that failure to 
down modulate HLA Class I could allow greater vulner-
ability to CTL killing of cells expressing early vs. late gene 
products from unintegrated HIV-1.
(See figure on next page.) 
Fig. 6 A single round of maximum T cell activation does not induce the expression of all latent unintegrated or integrated viruses. a Experimental 
design. eFluorhiGFP-negative cells were sorted on day 14 p.i., then cells were stimulated with Pro/TSA, αCD3/CD28 beads or medium only control 
(Ø). Three days later (day 17) all GFP-negative cells were purified in a second sort and 30,000 cells per well were (re)stimulated in triplicate. Efavirenz 
was added on days 14 and 17 to sorted cells as an added precaution against virus spread. b Flow cytometric analysis of cells at the end of the first 
three day treatment. GFP+ cells (light grey dots) are overlaid on GFP-negative cells (black dots). Undivided cells lie above the red lines. c The percent-
age of GFP+ cells generated after the first round of stimulation calculated based on the total number of GFP+ of the cells placed in the wells on 
day 14. d Flow analysis of cells after the restimulation. Cells that remained GFP-negative after the first round of stimulation were sorted and equal 
numbers of these cells were re-stimulated with Pro/TSA, αCD3/CD28beads or medium alone (Ø). e The percentage of GFP+ cells generated after 
the second round of stimulation calculated based on the total number of GFP+ of the cells placed in the wells on day 17. Mean and SD for each 
condition are shown
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Fig. 7 Gene expression from uDNA fails to down modulate HLA Class I but is efficiently recognized by HIV-1-specific CTL. a Unintegrated HIV-1 
down modulates CD4 in both resting (left) and activated (right) CD4 T cells. Resting IL-4 treated CD4 T cells were infected then analyzed 6 days after 
infection with Integrase wild type (Int-WT) or Integrase mutant (Int-D116N) HIV-1 GFP reporter viruses (left). One half of the cells were then activated 
with αCD3/CD28 beads then analyzed 2 days later (right). Activation caused a loss of a portion of GFP+ cells, resulting in fewer GFP+ at the time of 
analysis. The positive control CD4 down modulation data for the integrase WT virus was also a positive control in [43]. b Only integration-competent 
HIV-1 down modulates HLA A2 in resting (left) and post-infection activated (right) CD4 T cells. Cells were treated as in A but stained with an anti-HLA 
A2 antibody. c CD8+ cytotoxic T cells that recognize defined Gag and Nef epitopes (see materials and methods) specifically kill GFP+ cells infected 
with Int-WT or Int-D116N HIV-1. Killing was measured by loss of GFP+ cells, with non-specific killing of HLA Class I mismatched controls subtracted 
from the total. One of two representative experiments is shown
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Discussion
The findings presented here and in our prior studies [6, 
14, 68] challenge the notion that uDNA is inevitably a 
replicative dead end. Instead, latency, gene expression 
and virus production from unintegrated HIV-1 DNA are 
natural and possibly unavoidable consequences of the 
direct infection of resting CD4 T cells. In this in vitro set-
ting, we found evidence that gene expression from uDNA 
is regulated somewhat differently from iDNA during 
productive infection, as only uDNA required an interval 
of several days after infection to obtain responsiveness 
to activating agents. Furthermore, latent uDNA demon-
strated a wider dynamic range of responses to latency 
reversing agents and slower activation kinetics compared 
to latent integrated proviruses. Our prior work demon-
strated that uDNA but not iDNA depends on virion-
associated Vpr for expression in resting T cells further 
demonstrates qualitative differences in gene regulation 
between these forms of HIV-1 genomes [6].
HIV-1 uDNA surprisingly had a persistence advan-
tage over integrated proviruses in resting CD4 T cells, 
which we attribute to reduced cytotoxicity resulting from 
uDNA’s lower gene expression. As a result, resting CD4 
T cells expressed proteins and viruses from unintegrated 
genomes for longer than from integrated proviruses. The 
extended persistent expression from uDNA vs. iDNA 
was evident both during initial infection of cells and after 
reversal of latency. We also found that uDNA failed to 
down modulate HLA Class I surface expression on rest-
ing CD4 T cells, and HIV-1-specific CTL efficiently killed 
cells infected with unintegrated HIV-1. Thus, in  vivo, 
uDNA may contribute to the development of anti-HIV-1 
immune responses and to immune-dependent cell loss.
The de novo synthesis of virions from unintegrated 
HIV-1 requires a particular set of conditions that is clearly 
not the majority circumstance in  vivo, and virus produc-
tion by unintegrated HIV-1 in resting CD4 T cells is usu-
ally about one order of magnitude lower than from viruses 
which were capable of integration. Importantly, in  vivo, 
most viruses are generated from activated T cells, which 
generate several-fold more viruses than resting T cells [69], 
and which we confirmed in [6] do not support high level 
gene expression and de novo virus production from uDNA. 
Thus, the finding that uDNA is capable of latency and virus 
production do not challenge the accepted view that HIV-1 
predominantly replicates via the successfully integrated 
provirus. These findings are also consistent with the docu-
mented efficacy of raltegravir in vivo. We have identified an 
exception to the rule regarding the necessity of integration 
for de novo virus production and persistence. Intriguingly a 
recent study observed persistence of an integrase-defective 
HIV-1 in a patient [70], and infectious virus production 
from uDNA has recently been reported in T cell lines [71].
Investigations into the regulation of HIV-1 latency 
rely heavily on in  vitro models, with several promi-
nent systems utilizing direct infection of resting T cells 
(reviewed in [30]). In light of the results presented here, 
the contribution of uDNA to systems employing direct 
infection of resting and/or non-proliferating cells war-
rants investigation, as these systems may generate 
some of their output (RNA, virions, GFP+ cells) from 
unintegrated HIV-1 DNA, especially when stimulation 
is provided at least 5  days after infection. In addition, 
the procedure we established to reveal HIV–1 replica-
tion from uDNA [6] parallels the protocols developed to 
characterize in vivo latency: culture resting CD4 T cells 
from HIV+ individuals ex  vivo for about 6  days, then 
activate them [56, 72, 73]. This culture period was per-
formed so that pre-integration complexes in recently 
infected cells, which have a half-life of 1 day [40], would 
disintegrate and the cDNA would not integrate in 
response to T cell activation. Our studies suggest that 
these procedures would in fact optimize gene expres-
sion from any remaining unintegrated HIV-1. On the 
other hand, when infected cells proliferate, uDNA gene 
expression does not lead to de novo virus production 
[6], so systems in which activated and dividing T cells 
are infected are unlikely to generate such high levels of 
uDNA gene expression [74, 75]. The use of a prolifera-
tion tracking dye (eFluor670) allowed us to isolate only 
the non-proliferated cells for study of the in vitro gener-
ated latent reservoir, where we found the vast majority 
of latent infection. This technique is potentially useful 
in other models of HIV latency where the cells have 
been stimulated or activated prior to infection.
The potential of shock and kill therapies to eliminate 
latent reservoirs will depend upon these cells dying after 
virus activation, either via viral cytopathic effects or by 
immune killing [76], which has been cast into some 
doubt [77]. Our data here indicate that gene expression 
from uDNA displays slower kinetics and is more benign 
to host cells than from integrated proviruses, so viral 
cytopathicity is a particularly unreliable mechanism for 
eliminating cells expressing HIV-1 from uDNA. The lack 
of uDNA cytopathicity in resting CD4 T cells counterin-
tuitively translated into the aforementioned persistence 
of unintegrated vs. integrated genomes in our system. 
The generation of uDNA may bias against the kill portion 
of investigations performing direct infection of resting T 
cells.
Success of shock and kill will also depend upon activat-
ing all latent replication competent genomes; however, 
this task is complicated by the multifactorial nature of 
HIV-1 latency [78]. Among these factors, the availability 
and activity of transcription factors in cells of varying lin-
eages and activation states, the installation of epigenetic 
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controls, and virus integration into chromosomal regions 
that favor or disfavor gene expression can all compli-
cate the development of universally effective LRA [79, 
80]. Additionally, cellular activation does not necessarily 
induce all latent genomes [60, 81], and subpopulations 
of latently infected cells may display varying “degrees 
of latency” [82] or are regulated with a strong stochas-
tic component [81, 83]. This variability obtains even to 
clonal latent cell lines [38]. Here, we provide evidence for 
a further complication that can apply to, at least, in vitro 
models of latency: unintegrated HIV-1 genomes con-
tribute to latency when resting CD4 T cells are directly 
infected, and, as has observed for integrated proviruses, 
a subset of latent uDNA genomes resist activation by sin-
gle or double stimulation and contain a strong stochastic 
component to their expression. Our finding that uDNA 
gene expression is regulated by somewhat different rules 
than integrated proviruses could also complicate in vitro 
testing of therapeutics to purge viral reservoirs.
Two basic and non-exclusive models for the establish-
ment of HIV-1 latency have been proposed. Siliciano 
and Chun, after analyzing quiescent blood CD4 T cells, 
initially suggested that a rapid return to quiescence of 
recently infected activated cells can induce transcrip-
tional silencing, as necessary transcription factors are 
withdrawn. This model has the logical benefits that (1) 
most in  vivo latency in blood resides within previously 
activated memory CD4 T cells, and (2) it has been com-
monly accepted, based on studies of purified blood T 
cells, that quiescent (resting) CD4 T cells are poorly 
infectible, though infection and latency are possible even 
without stimulation [24]. However, the blood contains 
only 2 % of the body’s lymphocytes, with 98 % resident in 
tissues. Lymphoid and mucosal tissues are the predomi-
nant sites of HIV-1 replication, depletion and latency [29, 
84]. Microenvironmental factors in tissues enable resting 
CD4 T cells to be directly infected by HIV-1, and these 
cells are the dominant targets of early infection [29]. It 
has also been shown that infection of both resting cells 
from lymphoid tissues and activated T cells results in 
rapid establishment of latency [25]. Thus, a possible sec-
ond mechanism contributing to HIV-1 latency has been 
gaining traction, in which direct infection of resting but 
permissive cells allows HIV-1 to rapidly enter latency 
immediately or soon after reverse transcription and inte-
gration [24]. Within this scenario, the present work dem-
onstrates that latency and ultimately virus replication can 
be established in the absence of integration.
The responses of latent uDNA to the panel of latency 
reversing agents, measured as the induction of GFP+ 
cells and virions from sorted GFP-negative cells treated 
with raltegravir, obeyed the same basic pattern as when 
integration was allowed to proceed. However, the 
dynamic range of de novo virus production was sub-
stantially greater from unintegrated HIV-1, with weak 
stimuli inducing roughly equal numbers of GFP+ cells 
and 7–20  % as many virions as when integration is not 
blocked, while strong stimuli induced 2–3 times as 
many GFP+ cells and 30–66  % as many virions within 
24  h and up to >200  % more virions over 3  days. Thus, 
as the strength of the stimulus increased, relatively more 
uDNA genomes were recruited out of latency compared 
with integrated proviruses. This greater dynamic range 
of uDNA responses to LRA suggests that uDNA tran-
scription is regulated differently from iDNA. Chromatin 
structures that are proximal to the HIV-1 transcriptional 
regulatory regions, chief among these being promoter-
proximal nucleosomes, regulate the susceptibility of 
HIV-1 to transcriptional activation. The ability of histone 
deacetylase inhibitors to reverse latency is thought to 
be due at least in part to the displacement of promoter-
proximal nucleosomes following histone acetylation. The 
responsiveness of uDNA from HIV-1 and other retro-
viruses to HDACi, which has been observed before by 
others and by us [6, 44–46], is an indication that uDNA 
is also regulated by chromatin [44]. HDACi also acti-
vate many cellular genes, so the influences of HDACi on 
HIV-1 expression are likely complex and include multiple 
indirect effects. Nevertheless, our conclusion that uDNA 
is transcriptionally regulated by a set of criteria some-
what different from iDNA is supported by the notion that 
uDNA would lack chromosomal positional effects that 
an integrated gene would be subjected to, such as inte-
gration sites which favor or disfavor transcription, and 
integration near transcriptional regulatory sequences of 
cellular genes. In addition, Vpr’s ability to transactivate 
uDNA [85], and our prior demonstration that Vpr is the 
critical determining factor in establishing uDNA but not 
iDNA transcriptional competence in resting CD4 T cells, 
emphasizes the differential transcriptional regulation of 
uDNA and iDNA [6]. Use of Δvpr HIV-1 vectors to infect 
resting CD4 T cells would fail to achieve expression from 
unintegrated viral DNA and could account for some of 
the variability among systems [86]. How Vpr may con-
tribute to latency regulation is not clear, but some prior 
studies, including those from one of us, have indicated 
that Vpr can reactivate latent proviruses [87–90]. More 
recently, the cellular protein family TASK and the viral 
accessory protein Vpu has been shown to specifically 
down-modulate HIV-1 uDNA transcription in a NF-κB-
depended manner [91].
Antiviral immunity, particularly cytotoxic T cells, 
is envisioned to assist eradication of cells containing 
recently activated viruses. However, CTL killing in this 
scenario cannot necessarily be taken for granted [77, 92], 
and CTL responses may not be efficient at sites of HIV-1 
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replication in lymphoid tissues [93]. We observed that 
uDNA expression is unable to efficiently down modu-
late HLA Class I expression in resting or CD4 T cells that 
were subsequently activated, despite being able to down 
modulate CD4 expression [64]. HLA Class I is targeted 
by HIV-1 Nef, which has been shown previously to be 
expressed from uDNA, however, relatively higher levels 
of Nef are required to induce HLA Class I down modu-
lation than CD4 down modulation. We predicted that 
failure to down modulate HLA Class I might leave cells 
expressing HIV-1 from uDNA particularly vulnerable 
to CTL killing. We observed that both Nef-specific and 
Gag-specific CTL killed autologous target cells infected 
either with integrase wild type HIV-1 or integrase defec-
tive virus. Interestingly, cells infected with integrase 
defective virus were killed more efficiently than WT virus 
by the Nef-specific CLT but less efficiently by the Gag 
CTL. It is tempting to speculate that this relates to the 
relative inefficiency of Gag expression by uDNA, espe-
cially in replicating cells [6]. Recent studies have shown 
that the viral reservoir is influenced by the susceptibility 
of cells to CTL killing [67, 94], and it will be important 
to examine how uDNA expression sensitizes various cell 
types at different activation states to these processes.
Methods
Viruses
Viruses have been described previously [6, 14, 37, 43]. 
With the exception of Fig. 5a which employed an Env+ 
virus, infectious virions were generated by co-trans-
fection of 293T cells with a plasmid expressing the env 
gene-defective reporter virus and a plasmid expressing 
the CXCR4 trophic HIV-1 NL4-3 envelope, as described 
previously [6, 14, 37]. Virus stocks were filtered through 
a 0.45  μm pore-sized filter and treated with benzonase 
(50 μ/ml, Novagen) to remove residual plasmid remain-
ing from transfections, as described [14].
Cells and infections
Peripheral blood buffy coats from HIV–1-negative adults 
were purchased from the New York Blood Center. Iso-
lation, culture, IL–4 treatment, eFluor670 staining and 
infection of resting CD4 T cells have been described 
previously [6]. p24gag ELISA analysis on viral stocks 
indicated a range of 175–320 ng p24gag/106 cells except 
as indicated in Additional file 1: Fig S3. The titers of the 
virus stocks were routinely determined by TaqMan RT-
qPCR for HIV-1 RNA and normalized as previously 
described [6]. Raltegravir (1  μM in water) was added 
immediately after infection and supplemented at day 3 
and day 7 after infection. Maximally effective raltegravir 
dose in resting CD4 T cells was determined in [6] to be 
0.3 µM. The HIV-protease inhibitor indinavir (IND) was 
used at 2  μM in water and the NNRTi efavirenz (EFV) 
was used at 1  μg/ml in DMSO. All antiretrovirals were 
obtained from the NIH AIDS Research and Reference 
Reagent Program.
Stimulation of cells with latency reversing agents
The following conditions were utilized: αCD3/CD28 T 
cell activation beads (1  μl/40,000 cells; Life Technolo-
gies), PHA-L (3  μg/ml in PBS; Sigma), TNF-α (10  ng/
ml in PBS; Invitrogen), PMA (16.2 μM in DMSO; Fisher 
Scientific), prostratin (Pro; 330 nM in DMSO; Santa Cruz 
Biotechnology), bryostatin-1 (30  nM in DMSO; Santa 
Cruz Biotechnology), trichostatin A (TSA; 130  nM in 
DMSO; Fisher Scientific), JQ1 (1  μM in DMSO; kindly 
provided by James E. Bradner, Dana Farber Cancer Insti-
tute, Boston, MA), disulfiram (50  nM in DMSO; Tocris 
Bioscience), HMBA (1  mM in dH2O; Sigma), valproic 
acid (5 mM in PBS, Sigma), SAHA (vorinostat; 335 nM in 
DMSO; Santa Cruz Biotechnology), scriptaid (1.8 μM in 
DMSO; Santa Cruz Biotechnology), oxamflatin (500 nM 
in DMSO; Santa Cruz Biotechnology) and DMSO carrier 
control (0.1 % [14 mM], specific to Pro/TSA; Sigma). In 
the latency activation experiments, GFP-negative cells 
were plated at 30,000 cells per well in 96-well plates for 
stimulation. A supernatant sample from each treatment 
was collected 24 h later or at the indicated time point and 
cell GFP expression was concurrently analyzed by flow 
cytometry. Synergy index was calculated based on pub-
lished methods [95]. Briefly: The percentage of GFP+ 
cells after stimulation by each drug was converted to fold 
induction by normalizing to the percentage of GFP+ cells 
in IL-4-only treatment. The fold induction of a combina-
tion treatment was then divided by the sum of the fold 
induction of each drug when used separately. A combina-
tion with an index of >1 was considered synergistic, while 
an index of 1 was considered to be additive and <1 was 
considered as inhibitory.
Flow cytometry
Flow cytometric analysis was performed on a FAC-
Sort flow cytometer (Becton–Dickinson) upgraded to 3 
lasers and 5 color channels as previously described [6]. 
Cell proliferation was calculated using the Prolifera-
tion platform of the FlowJo software based on eFluor670 
intensity. Anti-CD4 (RPA-T4), Anti-HLA Class I (HLA 
A2) PerCP-Cy 5.5 (BB7.2), Anti-HLA-DR PerCP-Cy 5.5 
(G46-6) and Anti-HSA-PE (M1/69) antibodies were pur-
chased from BD Biosciences. Anti-CD69 PerCP-Cy5.5 
(FN50), and isotype control mouse IgG1κ PerCP-Cy5.5 
(MOPC-21) antibodies were purchased from BioLeg-
end. Anti-CD25 PerCP-Cy 5.5 (BC96) antibody was from 
eBioscience. Cell sorting was performed using a BD FAC-
SAria sorter at the NYU Langone Medical Centre Office 
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of Collaborative Science Flow Cytometry Core Facility. 
Flow cytometry for the CTL killing assay was performed 
at the UAB Center for AIDS Research Flow Cytometry 
Core. Intracellular DNA and RNA were stained with 
7-aminoactinomycin D (7-AAD) and pyronin Y (PY) as 
previously described [96].
MACS separation of productively infected 
and non‑productively infected cells
After infection with murine HSA (CD24)-expressing 
reporter virus, primary CD4 T cells were treated at 1 day 
p.i. with pronase (Fisher Scientific) to remove residual 
HSA molecules from the initial infection as in [14]. At the 
indicated time points, live cells were purified on a Ficoll-
Paque (GE Life Sciences) gradient, stained with a phyco-
erythrin (PE) labeled anti-mCD24 antibody (M1/69, BD 
Biosciences) and then bound to anti-PE magnetic micro-
beads (Miltenyi Biotec). HSA Positive and negative cells 
were separated using the MACS system (Miltenyi Biotec) 
according to manufacturer’s protocol. Purity was rou-
tinely >95 %. Cell survival was measured by forward and 
side scatter analysis.
PCR methods for quantification of HIV‑1 DNA and RNA
All methods, including primers and TaqMan probes have 
been previously described [6, 43]. Briefly, DNA from cells 
was purified using the DNeasy Blood & Tissue kit or the 
AllPrep kit (Qiagen). Cell associated RNA and viral RNA 
in culture medium were prepared using the RNeasy kit 
(Qiagen). DNA was analyzed using the QuantiTect Probe 
PCR kit (Qiagen) and RNA was analyzed by RT-qPCR 
using the QuantiTect Probe RT-PCR kit (Qiagen). Inte-
grated HIV-1 was detect by Alu PCR as described [6].
CTL cell killing assay
HLA I-restricted CD8+ Cytotoxic T cell lines reactive 
against HIV-1 peptides were developed from HIV-1+ 
individuals as described [97]. CTL clone 2B6 recognizes 
HLA B*5301 restricted Gagp24-QW9 (QASQEVKNW) 
epitope in Nef, while clone 2A3 recognizes HLA B*4002 
restricted Nef-KL9 (KEKGGLEGL) epitope. Both these 
clones were obtained from a chronically HIV clade B 
infected patient expressing HLA-A*02(01, 09)/A*3201; 
B*4002/B*5301 and Cw*0202/Cw*0401. EBV trans-
formed B lymphoblastoid cell-lines  (BLCL) were devel-
oped from this patient’s PBMC for use as targets in the 
killing assay. An HLA-I mismatched BLCL was used as a 
negative control (HLA-A*2904/A*3002; B*1503/B*5802; 
Cw*0202/Cw*0602). Target cells were infected with 
VSV-G pseudotyped NLENG1-ES-IRES or NLENG1-ES-
IRES-D116N as described [14, 37], resulting in 5–20  % 
GFP+ cells. Two days after infection, 50,000 infected 
target cells were co-cultured for 4  h with the CTL a 
three CTL:target ratios indicated in Fig.  7c. Cells were 
then harvested and stained with anti-CD19-PE-Cy7, 
anti-CD3-Pacific Blue, and anti-CD8-PerCP-Cy5.5 (BD 
Biosciences). Flow cytometry was performed on a BD 
FACSAria at the University of Alabama at Birmingham 
Center for AIDS Research Flow Cytometry Core Facility. 
Live cells were identified by side scatter and forward scat-
ter profile, and live CD19+ CD3−CD8− cells were ana-
lyzed for percent GFP expression. Specific CTL killing of 
GFP+ target cells was calculated in two steps: The GFP+ 
cells remaining after CTL exposure was calculated as a 
percentage of the number of CD19+ CD3−CD8−GFP+ 
cells present without CTL, then non-specific killing of 
HLA-mismatched target cells (<10 % in all instances) was 
then subtracted from this number for each CTL:target 
ratio. This number was graphed as the Percent Specific 
Killing in Fig. 7c.
Additional file
Additional file 1: Figure S1 (supplement to Fig. 1). Integrase D116N 
mutant expression in resting CD4 T cells. An experiment performed 
independently from those in Figs. 1 and 2 was performed using a differ-
ent donor. (A) Kinetics of virus expression with and without stimulation. 
(B) Loss of GFPhi  population similar to raltegravir treatment of WT virus.    
Figure S2 (supplement to Fig. 1). Protein, RNA and DNA in GFP+ and 
GFP- cells at day 14 post infection. (A) HIV-GFP expression in cells at day 14 
for analysis in E. Data are representative of >5 independent experiments 
using cells from different donors. MFI = mean fluorescence intensity of 
GFP. (B) Intracellular HIV-1 RNA in sorted cells from integration permissive 
(No RAL) and integration inhibited (+RAL) cultures. Early Rev-independent 
Fully spliced RNA, and late Rev-dependent unspliced RNA were quantified 
by RT-qPCR (see methods). Data are normalized to Fully spliced RNA in the 
GFP+ No RAL cells set as 100%. Data from one of two similar experiments 
is shown. Standard deviations are from PCR triplicates. Non-proliferated 
cells were sorted for this analysis (Fig S4A-B). (C) qPCR analysis of Total 
and Integrated HIV-1 DNA in cells from Fig. 1E-F. Infection in the presence 
of raltegravir resulted in less than 1 in 500 GFP+ cells containing an 
integrated provirus.    Figure S3 (supplement to Fig. 1). Lack of influence 
of MOI on the timing of HIV-1 gene expression and on No RAL vs. + 
RAL latency in resting CD4 T cells. (A) Cells were infected as in Figure 1 
except that different doses of HIV-1 were applied. Figure 1 employs 300ng 
p24gag per million cells. Note that the Y axis scales are adjusted to allow 
comparison of relative kinetics at different MOI. (B) Relative amounts of 
latency for No RAL and +RAL infections remain constant with varying 
MOI. GFP-negative cells from each infection were sorted at Day 14 p.i. by 
FACS and stimulated with Pro/TSA in triplicates or DMSO. Expression of 
GFP one day after stimulation is shown. Data representative of 3 inde-
pendent experiments with 3 different donors.    Figure S4 (supplement to 
Fig 1). Homeostatic proliferation of IL-4 treated cells and resting status of 
the non-productively infected cells. (A) eFluor670 and GFP expression on 
day 14 p.i. Sorting gates are indicated by red boxes. Data are representa-
tive of >5 independent experiments using cells from different donors. (B) 
Analysis of cell proliferation on the day of sorting. The FlowJo Proliferation 
Platform was used to calculate the percentage of cells that had divided at 
least once. (C) Expression of T cell activation markers CD69, HLA-DR and 
CD25 on the eFluorhiGFP-negative cells one day after sorting. Data are 
representative of three independent experiments. (D) 7AAD-Pyronin Y 
staining of eFluorhiGFP-negative cells one day after sort. As a positive con-
trol for cell cycle progression, uninfected CD4 T cells were activated with 
αCD3/CD28 beads four days prior to analysis. The arrow with * indicates 
cells with increased DNA content but low RNA levels that are apparently 
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